Namkyoung Kim
Overview
Explore the profile of Namkyoung Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
24
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim Y, Song J, Kim N, Sim T
RSC Med Chem
. 2025 Feb;
PMID: 39925737
Cholangiocarcinoma (CCA) is a diverse group of epithelial malignant tumors arising from the biliary tract, characterized by high molecular heterogeneity. It is classified into intrahepatic (iCCA) and extrahepatic CCA (eCCA)...
2.
Nam Y, Kim C, Han J, Ryu S, Cho H, Song C, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893284
The authors would like to make a correction to the previous article [...].
3.
Kim S, Kim S, Kim S, Kim N, Lee S, Yi H, et al.
Adv Sci (Weinh)
. 2023 Nov;
11(4):e2306401.
PMID: 38032124
Chemically modified proteins have diverse applications; however, conventional chemo-selective methods often yield heterogeneously labeled products. To address this limitation, site-specific protein labeling holds significant potential, driving extensive research in this...
4.
Kim Y, Seo P, Jeon E, You I, Hwang K, Kim N, et al.
Cell Chem Biol
. 2023 Aug;
30(11):1414-1420.e5.
PMID: 37567174
Chemically induced protein degradation is a powerful strategy for perturbing cellular biochemistry. The predominant mechanism of action for protein degrader drugs involves an induced proximity between the cellular ubiquitin-conjugation machinery...
5.
Kim N, Park C, Kim Y, Ryu S, Cho H, Nam Y, et al.
Eur J Med Chem
. 2023 Jul;
259:115635.
PMID: 37494773
Necroptosis executed by RIPK3-mediated phosphorylation of MLKL is a programmed necrotic cell death and implicated with various diseases such as sterile inflammation. We designed and synthesized pyrido[3,4-d]pyrimidine derivatives as novel...
6.
Kim N, SenGupta S, Lee J, Dash U, Kim S, Kim H, et al.
Eur J Med Chem
. 2023 Jul;
259:115592.
PMID: 37478559
SbnE is an essential enzyme for staphyloferrin B biosynthesis in Staphylococcus aureus. An earlier study showed that natural product baulamycin A has in vitro inhibitory activity against SbnE and antibacterial...
7.
Nam Y, Kim C, Han J, Ryu S, Cho H, Song C, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612139
c-KIT is a promising therapeutic target against gastrointestinal stromal tumor (GIST). In order to identify novel c-KIT inhibitors capable of overcoming imatinib resistance, we synthesized 31 novel thiazolo[5,4-]pyridine derivatives and...
8.
Ryu S, Nam Y, Kim N, Shin I, Jeon E, Kim Y, et al.
J Med Chem
. 2022 Apr;
65(8):6017-6038.
PMID: 35436119
Although FGFR inhibitors hold promise in treating various cancers, resistance to the FGFR inhibitors caused by acquired secondary mutations has emerged. To discover novel FGFR inhibitors capable of inhibiting FGFR...
9.
Ryu S, Park J, Ham Y, Lim D, Kwiatkowski N, Kim D, et al.
J Med Chem
. 2022 Jan;
65(3):1915-1932.
PMID: 35029981
The polo-box domain (PBD) of Plk1 is a promising target for cancer therapeutics. We designed and synthesized novel phosphorylated macrocyclic peptidomimetics targeting PBD based on acyclic phosphopeptide PMQSpTPL. The inhibitory...
10.
Kim N, Shin I, Kim Y, Jeon E, Lee J, Lee C, et al.
Front Oncol
. 2021 Dec;
11:768022.
PMID: 34956887
RAS mutants are involved in approximately 30% of all human cancers and have been regarded as undruggable targets owing to relatively smooth protein surface and obscure binding pockets. In our...